RxDoctor Payments Data

David German, MD

Internal Medicine · Glasgow, KYNPI 1306946306

Payments from drug & device makers

$976in general payments, 2019–2025

Across 55 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$260
  • AbbVie$120
  • Johnson & Johnson$119
  • Portola Pharmaceuticals, LLC$78
  • AstraZeneca$74
  • Mylan Specialty L.p.$68
  • plus $257 from 9 others

What the payments were for

  • Food & beverage$976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$976 in reported general payments places this provider in the 60th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$77,284
Medicare patients
244
Services billed
717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$12,205
Breo ElliptaFluticasone/Vilanterol28$11,110
EliquisApixaban21$8,699
Novolog FlexpenInsulin Aspart18$3,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,176
Albuterol Sulfate HfaAlbuterol Sulfate13$372
Atorvastatin Calcium39$238
Pantoprazole Sodium30$222
Metoprolol Succinate21$178
Metoprolol Tartrate30$108
Cefdinir27$106
Amlodipine Besylate22$99
Levofloxacin17$98
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$97
Isosorbide Mononitrate ErIsosorbide Mononitrate17$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$119$12,20518 claims
GSKBreo Ellipta$51$11,11028 claims
PfizerEliquis$260$8,69921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Glasgow

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →